Detailed Report on Amgen Inc.: A Leading Biopharmaceutical Company

This report provides a detailed analysis of Amgen Inc., a prominent biopharmaceutical company. It begins with an introduction to biotechnology and then delves into Amgen's key characteristics, including its company profile, website link, and the technologies it employs, particularly recombinant DNA technology. The report highlights Amgen's product portfolio, such as Enbrel and Neulasta, and discusses its founders, start-up date, and significant funding, including the FDA's support for AMG 510, a drug targeting non-small cell lung carcinoma. The report also addresses Amgen's role in meeting healthcare needs, its stakeholders, and concludes by emphasizing the company's potential to provide future treatments for chronic illnesses. The report references several sources, including Amgen's official website, Bloomberg, Forbes, and a research paper on a biosimilar to bevacizumab.

Running head: BIOPHARMACEUTICAL COMPANY: AMGEN INC.
BIOPHARMACEUTICAL COMPANY: AMGEN, INC.
Name of the Student:
Name of the University:
Author note:

1BIOPHARMACEUTICAL COMPANY: AMGEN INC.
Introduction
The field of biotechnology encompasses the application of life forms or living organisms
in the development of technology or technological derivatives. The following paper will briefly
discuss on the key industrial components and characteristics identified with respect to a selected
biotechnological company, that is Amgen Inc.
Discussion: Understanding the Organization
Company Name, Website Link
The company so selected is ‘Amgen Inc.’, - an abbreviation of its previous name,
‘Applied Molecular Genomics Inc.’ It is an independent, multinational industry specializing as
one of the largest functioning biotechnology and biopharmaceutical companies across the
international market. Currently, the organization holds a workforce of approximately 5, 125
scientists and thus, one of the highest employment providers of 7.5 % of Ventura’s County’s
current employees. The link to the company’s website is as follows: http://www.amgen.com/
(Amgen Inc., 2020)
Technology
The organization centers its mission, values and foundational policy on the principle of
providing healthcare services and products developed with respect to DNA technology of the
recombinant type. Currently, the organization has specialized in the development of products
based on biochemistry and molecular biology technology. Prevalently used examples: Enbrel (a
pharmaceutical product with abilities of blocking tumor necrosis factor), Neulasta (an infection
preventive drug suitable for cancer patients undergoing chemotherapy with immunostimulator

2BIOPHARMACEUTICAL COMPANY: AMGEN INC.
properties) and additional antibody and protein based drugs, such as Vectibix, XGEVA, Prolia,
Epogen, Mimpara, Aranesp, Sensipar and Nplate (Bloomberg, 2020).
Founders, Start-up Date
The industry was established in the year 1980, after Winston Salsen and William Bowes
from the University of California and the Cetus Company, introduced the concept and idea of
Amgen to a scientific advisory board. The company witnessed George B as its first chief
executive officer in the year 1980, Gordon M. Binder in the year 1988 and finally Kevin W.
Sharer in the year 2000. Currently, from 2012, Robert A. Bradway has been serving as the
organization’s chief executive officer and president (Forbes, 2020).
Major Funding
The organization, from the year 2019, has been receiving funding from the Food and
Drug Administration for an experimental pharmaceutical and medicinal product AMG 510 – a
drug targeting the treatment of lung carcinoma of the non-small lung cell type. The drug
specifically targets carcinoma which are mutated with G12C KRAS (Seo et al., 2018).
Needs
By incorporating biotechnology in the development of innovative medical technology
and products, Amgen Inc. adheres to the long term, adverse disease and healthcare concerns of
patients with debilitating chronic and terminal illnesses. By additionally engaging in clinical
research and long term medical trials, Amgen Inc. also addresses public health needs of
availability of healthcare education and preventive disease strategies. Lastly, the
biopharmaceutical innovations by Amgen Inc. addresses the economic and social needs of
families of chronically ill patients (Amgen Inc., 2020).

3BIOPHARMACEUTICAL COMPANY: AMGEN INC.
Stakeholders
A range of pharmaceutical companies and major biotechnological organizations are
major stakeholders with corporate acquisitions in Amgen Inc. These include: Catherex, Onyx
Pharmaceuticals, Dezima Pharma, Kai Pharmaceuticals and deCODE genetics (Amgen Inc.,
2020)
Conclusion
This paper thus provides a brief yet detailed discussion with respect to the key
characteristics and industrial components of a biopharmaceutical company, Amgen Inc. To
conclude, the organization’s usage of innovative biotechnology can serve as future useful
treatments for chronic illnesses.

4BIOPHARMACEUTICAL COMPANY: AMGEN INC.
References
Amgen Inc. (2020). Amgen. Retrieved 8 February 2020, from https://www.amgen.com/.
Bloomberg. (2020). Amgen Inc. Retrieved 8 February 2020, from
https://www.bloomberg.com/profile/company/AMGN:US.
Forbes. (2020). Amgen. Retrieved 8 February 2020, from
https://www.forbes.com/companies/amgen/#32e0371d6ae3.
Seo, N., Polozova, A., Zhang, M., Yates, Z., Cao, S., Li, H., ... & Liu, J. (2018, May). Analytical
and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. In MAbs (Vol.
10, No. 4, pp. 678-691). Taylor & Francis.